Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
National Institutes of HealthPAR-25-070
CFDA Number
93.393
Funding Instrument
Other
Funding Level
Federal
Jurisdiction
US
Cost Sharing
No
Open Date
November 18, 2024
Close Date
January 7, 2027
Posted Date
November 18, 2024
Tags
HHS-NIH11
Related Health & Human Services Grants
NIH Brain Development Cohorts (NBDC) Biospecimen Access (X01 Clinical Trial Not Allowed)
National Institutes of Health
0d left
Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
National Institutes of Health
0d left
Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)
National Institutes of Health
0d left
Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
National Institutes of Health
0d left